supporter Sky High for Kids makes its mark in Memphis today as the first organization to add its name to the Advanced Research Center, the new state-of-the-art facility opening later this year on the St. Jude campus.
The Advanced Research Center builds on the St. Jude legacy of transformative innovations to understand and treat childhood cancer and other life-threatening diseases.
The Advanced Research Center, shown here during construction at St. Jude Children’s Research Hospital, will enable collaboration among scientists in several fields, including developmental neurobiology, which will be housed in the Sky High for Kids Research Floor.
(PRNewsfoto/ALSAC/St. Jude Children s Research Hospital)
New results challenge the current understanding of medulloblastoma
Scientists at St. Jude Children s Research Hospital and their colleagues have published a detailed account of SJMB03, a clinical trial for pediatric patients with medulloblastoma.
Additionally, they report results of the largest analysis of matched primary and relapsed medulloblastoma tumors to date. In both the clinic and the lab, results underscore the need for integrated molecular assessment of these tumors. The papers were published recently in the
Journal of Clinical Oncology.
Clinical trial confirms subgroups, highlights need for additional analysis
Medulloblastoma is among the most common malignant pediatric brain tumors. Previous research by St. Jude scientists and others has classified medulloblastoma into four distinct molecular groups: WNT and SHH (which are driven by their namesake genetic mutations), Group 3, and Group 4.